Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 633

1.

GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis.

Best J, Bechmann LP, Sowa JP, Sydor S, Dechêne A, Pflanz K, Bedreli S, Schotten C, Geier A, Berg T, Fischer J, Vogel A, Bantel H, Weinmann A, Schattenberg JM, Huber Y, Wege H, von Felden J, Schulze K, Bettinger D, Thimme R, Sinner F, Schütte K, Weiss KH, Toyoda H, Yasuda S, Kumada T, Berhane S, Wichert M, Heider D, Gerken G, Johnson P, Canbay A.

Clin Gastroenterol Hepatol. 2019 Nov 8. pii: S1542-3565(19)31267-4. doi: 10.1016/j.cgh.2019.11.012. [Epub ahead of print]

2.

A continuous-time hidden Markov model for cancer surveillance using serum biomarkers with application to hepatocellular carcinoma.

Amoros R, King R, Toyoda H, Kumada T, Johnson PJ, Bird TG.

Metron. 2019;77(2):67-86. doi: 10.1007/s40300-019-00151-8. Epub 2019 May 30.

3.

Correlation of serum zinc levels with pathological and laboratory findings in patients with nonalcoholic fatty liver disease.

Ito T, Ishigami M, Ishizu Y, Kuzuya T, Honda T, Ishikawa T, Toyoda H, Kumada T, Fujishiro M.

Eur J Gastroenterol Hepatol. 2019 Oct 30. doi: 10.1097/MEG.0000000000001587. [Epub ahead of print]

PMID:
31688305
4.

Liver stiffness does not affect ultrasound-guided attenuation coefficient measurement in the evaluation of hepatic steatosis.

Tada T, Kumada T, Toyoda H, Yasuda S, Sone Y, Hashinokuchi S, Ogawa S, Oguri T, Kamiyama N, Chuma M, Akita T, Tanaka J.

Hepatol Res. 2019 Oct 29. doi: 10.1111/hepr.13442. [Epub ahead of print]

PMID:
31661724
5.

Safety and efficacy of lenvatinib in elderly patients with unresectable hepatocellular carcinoma: a multicenter analysis with propensity score matching.

Tada T, Kumada T, Hiraoka A, Michitaka K, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Toyoda H, Nouso K, Tsutsui A, Nagano T, Itokawa N, Hayama K, Imai M, Joko K, Koizumi Y, Hiasa Y; Real-life Practice Experts for HCC (RELPEC) Study Group and the HCC 48 Group (Hepatocellular carcinoma experts from 48 clinics in Japan).

Hepatol Res. 2019 Oct 29. doi: 10.1111/hepr.13427. [Epub ahead of print]

PMID:
31660700
6.

Tenofovir Versus Entecavir for Hepatocellular Carcinoma Prevention in an International Consortium of Chronic Hepatitis B.

Hsu YC, Wong GL, Chen CH, Peng CY, Yeh ML, Cheung KS, Toyoda H, Huang CF, Trinh H, Xie Q, Enomoto M, Liu L, Yasuda S, Tanaka Y, Kozuka R, Tsai PC, Huang YT, Wong C, Huang R, Jang TY, Hoang J, Yang HI, Li J, Lee DH, Takahashi H, Zhang JQ, Ogawa E, Zhao C, Liu C, Furusyo N, Eguchi Y, Wong C, Wu C, Kumada T, Yuen MF, Yu ML, Nguyen MH.

Am J Gastroenterol. 2019 Oct 11. doi: 10.14309/ajg.0000000000000428. [Epub ahead of print]

PMID:
31634265
7.

Cure with Interferon Free DAA is Associated with Increased Survival in Patients with HCV related HCC from both East and West.

Dang H, Yeo YH, Yasuda S, Huang CF, Iio E, Landis C, Jun DW, Enomoto M, Ogawa E, Tsai PC, Le A, Liu M, Maeda M, Nguyen B, Ramrakhiani N, Henry L, Cheung R, Tamori A, Kumada T, Tanaka Y, Yu ML, Toyoda H, Nguyen MH.

Hepatology. 2019 Oct 14. doi: 10.1002/hep.30988. [Epub ahead of print]

PMID:
31610027
8.

Real-world experience of 12-week direct-acting antiviral regimen of glecaprevir and pibrentasvir in patients with chronic hepatitis C virus infection.

Toyoda H, Atsukawa M, Watanabe T, Nakamuta M, Uojima H, Nozaki A, Takaguchi K, Fujioka S, Iio E, Shima T, Akahane T, Fukunishi S, Asano T, Michitaka K, Tsuji K, Abe H, Mikami S, Okubo H, Okubo T, Shimada N, Ishikawa T, Moriya A, Tani J, Morishita A, Ogawa C, Tachi Y, Ikeda H, Yamashita N, Yasuda S, Chuma M, Tsutsui A, Hiraoka A, Ikegami T, Genda T, Tsubota A, Masaki T, Tanaka Y, Iwakiri K, Kumada T.

J Gastroenterol Hepatol. 2019 Oct 14. doi: 10.1111/jgh.14874. [Epub ahead of print]

PMID:
31609495
9.

B-Mode Ultrasonography versus Contrast-Enhanced Ultrasonography for Surveillance of Hepatocellular Carcinoma: A Prospective Multicenter Randomized Controlled Trial.

Kudo M, Ueshima K, Osaki Y, Hirooka M, Imai Y, Aso K, Numata K, Kitano M, Kumada T, Izumi N, Sumino Y, Ogawa C, Akazawa K.

Liver Cancer. 2019 Jul;8(4):271-280. doi: 10.1159/000501082. Epub 2019 Jun 6.

10.

The emergence of non-hypervascular hypointense nodules on Gd-EOB-DTPA-enhanced MRI in patients with chronic hepatitis C.

Toyoda H, Tada T, Yasuda S, Mizuno K, Sone Y, Kaneoka Y, Maeda A, Akita T, Tanaka J, Kumada T.

Aliment Pharmacol Ther. 2019 Dec;50(11-12):1232-1238. doi: 10.1111/apt.15490. Epub 2019 Oct 6.

PMID:
31588590
11.

G-protein-coupled receptor 40 agonist GW9508 potentiates glucose-stimulated insulin secretion through activation of protein kinase Cα and ε in INS-1 cells.

Hashimoto T, Mogami H, Tsuriya D, Morita H, Sasaki S, Kumada T, Suzuki Y, Urano T, Oki Y, Suda T.

PLoS One. 2019 Sep 9;14(9):e0222179. doi: 10.1371/journal.pone.0222179. eCollection 2019.

12.

Early Relative Change in Hepatic Function with Lenvatinib for Unresectable Hepatocellular Carcinoma.

Hiraoka A, Kumada T, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Tada T, Toyoda H, Nouso K, Tsutsui A, Nagano T, Itokawa N, Hayama K, Imai M, Joko K, Koizumi Y, Hiasa Y, Michitaka K; On behalf of the Real-Life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan).

Oncology. 2019 Aug 29:1-7. doi: 10.1159/000502095. [Epub ahead of print]

PMID:
31466068
13.

Serum Nutritional Markers as Prognostic Factors for Hepatic and Extrahepatic Carcinogenesis in Japanese Patients with Nonalcoholic Fatty Liver Disease.

Ito T, Ishigami M, Ishizu Y, Kuzuya T, Honda T, Ishikawa T, Toyoda H, Kumada T, Fujishiro M.

Nutr Cancer. 2019 Aug 21:1-8. doi: 10.1080/01635581.2019.1653474. [Epub ahead of print]

PMID:
31433263
14.

Risk Factors for Cerebral Infarction in Duchenne Muscular Dystrophy: Review With our 2 Cases.

Nozaki F, Kusunoki T, Kumada T, Shibata M, Fujii T.

J Stroke Cerebrovasc Dis. 2019 Sep;28(9):2453-2458. doi: 10.1016/j.jstrokecerebrovasdis.2019.06.023. Epub 2019 Jul 13. Review.

PMID:
31311695
15.

Important Clinical Factors in Sequential Therapy Including Lenvatinib against Unresectable Hepatocellular Carcinoma.

Hiraoka A, Kumada T, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Tada T, Toyoda H, Nouso K, Tsutsui A, Nagano T, Itokawa N, Hayama K, Imai M, Joko K, Tanaka H, Tamai T, Koizumi Y, Hiasa Y, Michitaka K, Kudo M; Real-life Practice Experts for HCC (RELPEC) Study Group; HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan).

Oncology. 2019;97(5):277-285. doi: 10.1159/000501281. Epub 2019 Jul 15.

PMID:
31307035
16.

Evaluation of 8-week glecaprevir/pibrentasvir treatment in direct-acting antiviral-naïve noncirrhotic HCV genotype 1 and 2infected patients in a real-world setting in Japan.

Ikeda H, Watanabe T, Atsukawa M, Toyoda H, Takaguchi K, Nakamuta M, Matsumoto N, Okuse C, Tada T, Tsutsui A, Yamashita N, Kondo C, Hayama K, Kato K, Itokawa N, Arai T, Shimada N, Asano T, Uojima H, Ogawa C, Mikami S, Ikegami T, Fukunishi S, Asai A, Iio E, Tsubota A, Hiraoka A, Nozaki A, Okubo H, Tachi Y, Moriya A, Oikawa T, Matsumoto Y, Tsuruoka S, Tani J, Kikuchi K, Iwakiri K, Tanaka Y, Kumada T.

J Viral Hepat. 2019 Nov;26(11):1266-1275. doi: 10.1111/jvh.13170. Epub 2019 Aug 9.

PMID:
31278795
17.

Usefulness of Attenuation Imaging with an Ultrasound Scanner for the Evaluation of Hepatic Steatosis.

Tada T, Iijima H, Kobayashi N, Yoshida M, Nishimura T, Kumada T, Kondo R, Yano H, Kage M, Nakano C, Aoki T, Aizawa N, Ikeda N, Takashima T, Yuri Y, Ishii N, Hasegawa K, Takata R, Yoh K, Sakai Y, Nishikawa H, Iwata Y, Enomoto H, Hirota S, Fujimoto J, Nishiguchi S.

Ultrasound Med Biol. 2019 Oct;45(10):2679-2687. doi: 10.1016/j.ultrasmedbio.2019.05.033. Epub 2019 Jul 3.

PMID:
31277922
18.

Natural history of liver-related disease in patients with chronic hepatitis C virus infection: An analysis using a Markov chain model.

Tada T, Toyoda H, Yasuda S, Miyake N, Kumada T, Kurisu A, Ohisa M, Akita T, Tanaka J.

J Med Virol. 2019 Oct;91(10):1837-1844. doi: 10.1002/jmv.25533. Epub 2019 Jul 16.

19.

Cumulative jerk as an outcome measure in nonambulatory Duchenne muscular dystrophy.

Fujii T, Takeshita E, Iwata Y, Yajima H, Nozaki F, Mori M, Kumada T.

Brain Dev. 2019 Oct;41(9):796-802. doi: 10.1016/j.braindev.2019.06.002. Epub 2019 Jun 15.

PMID:
31213334
20.

The course of elderly patients with persistent hepatitis C virus infection without hepatocellular carcinoma.

Mizuno K, Toyoda H, Yasuda S, Tada T, Kumada T, Sone Y, Tanaka J.

J Gastroenterol. 2019 Sep;54(9):829-836. doi: 10.1007/s00535-019-01595-5. Epub 2019 Jun 3.

PMID:
31161311
21.

Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions-Multicenter analysis.

Hiraoka A, Kumada T, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Tada T, Toyoda H, Nouso K, Tsutsui A, Nagano T, Itokawa N, Hayama K, Imai M, Joko K, Koizumi Y, Hiasa Y, Michitaka K, Kudo M; Real-life Practice Experts for HCC (RELPEC) Study Group, HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan).

Cancer Med. 2019 Jul;8(8):3719-3728. doi: 10.1002/cam4.2241. Epub 2019 May 24.

22.

Artificial Optic Flow Guides Visual Attention in a Driving Scene.

Higuchi Y, Inoue S, Hamada H, Kumada T.

Hum Factors. 2019 May 24:18720819847022. doi: 10.1177/0018720819847022. [Epub ahead of print]

PMID:
31125278
23.

Trends and Efficacy of Interferon-Free Anti-hepatitis C Virus Therapy in the Region of High Prevalence of Elderly Patients, Cirrhosis, and Hepatocellular Carcinoma: A Real-World, Nationwide, Multicenter Study of 10 688 Patients in Japan.

Toyoda H, Atsukawa M, Uojima H, Nozaki A, Tamai H, Takaguchi K, Fujioka S, Nakamuta M, Tada T, Yasuda S, Chuma M, Senoh T, Tsutsui A, Yamashita N, Hiraoka A, Michitaka K, Shima T, Akahane T, Itobayashi E, Watanabe T, Ikeda H, Iio E, Fukunishi S, Asano T, Tachi Y, Ikegami T, Tsuji K, Abe H, Kato K, Mikami S, Okubo H, Shimada N, Ishikawa T, Matsumoto Y, Itokawa N, Arai T, Tsubota A, Iwakiri K, Tanaka Y, Kumada T.

Open Forum Infect Dis. 2019 Apr 15;6(5):ofz185. doi: 10.1093/ofid/ofz185. eCollection 2019 May.

24.

Type 2 diabetes mellitus: A risk factor for progression of liver fibrosis in middle-aged patients with non-alcoholic fatty liver disease.

Tada T, Toyoda H, Sone Y, Yasuda S, Miyake N, Kumada T, Tanaka J.

J Gastroenterol Hepatol. 2019 May 21. doi: 10.1111/jgh.14734. [Epub ahead of print]

PMID:
31115065
25.

Long-term prognosis of liver disease in patients with chronic hepatitis B virus infection receiving nucleos(t)ide analogue therapy: an analysis using a Markov chain model.

Tada T, Toyoda H, Yasuda S, Miyake N, Kumada T, Kurisu A, Ohisa M, Akita T, Tanaka J.

Eur J Gastroenterol Hepatol. 2019 Nov;31(11):1452-1459. doi: 10.1097/MEG.0000000000001434.

PMID:
31082998
26.

Dynamic Evaluation of Liver Fibrosis to Assess the Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C Who Achieved Sustained Virologic Response.

Toyoda H, Tada T, Yasuda S, Mizuno K, Ito T, Kumada T.

Clin Infect Dis. 2019 May 6. pii: ciz359. doi: 10.1093/cid/ciz359. [Epub ahead of print]

PMID:
31056696
27.

Validation of Modified ALBI Grade for More Detailed Assessment of Hepatic Function in Hepatocellular Carcinoma Patients: A Multicenter Analysis.

Hiraoka A, Kumada T, Tsuji K, Takaguchi K, Itobayashi E, Kariyama K, Ochi H, Tajiri K, Hirooka M, Shimada N, Ishikawa T, Tachi Y, Tada T, Toyoda H, Nouso K, Joko K, Hiasa Y, Michitaka K, Kudo M.

Liver Cancer. 2019 Mar;8(2):121-129. doi: 10.1159/000488778. Epub 2018 Jun 11.

28.

Cerebellar activation associated with model-based estimation of tool-use consequences.

Ueda S, Sakai H, Ueno K, Cheng K, Kumada T.

Behav Brain Funct. 2019 Apr 16;15(1):8. doi: 10.1186/s12993-019-0158-y.

29.

Impact of Branched-Chain Amino Acid Granule Therapy in Patients with Hepatocellular Carcinoma Who Have Normal Albumin Levels and Low Branched-Chain Amino Acid to Tyrosine Ratios.

Tada T, Kumada T, Toyoda H, Yasuda S, Koyabu T, Nakashima M.

Nutr Cancer. 2019;71(7):1132-1141. doi: 10.1080/01635581.2019.1597905. Epub 2019 Apr 6.

PMID:
30955354
30.

Circulating microRNA-1246 as a possible biomarker for early tumor recurrence of hepatocellular carcinoma.

Chuma M, Toyoda H, Matsuzaki J, Saito Y, Kumada T, Tada T, Kaneoka Y, Maeda A, Yokoo H, Ogawa K, Kamiyama T, Taketomi A, Matsuno Y, Yazawa K, Takeda K, Kunisaki C, Ogushi K, Moriya S, Hara K, Nozaki A, Kondo M, Fukuda H, Numata K, Tanaka K, Maeda S, Sakamoto N.

Hepatol Res. 2019 Jul;49(7):810-822. doi: 10.1111/hepr.13338. Epub 2019 May 23.

PMID:
30920086
31.

The efficacy and safety of glecaprevir plus pibrentasvir in 141 patients with severe renal impairment: a prospective, multicenter study.

Atsukawa M, Tsubota A, Toyoda H, Takaguchi K, Nakamuta M, Watanabe T, Michitaka K, Ikegami T, Nozaki A, Uojima H, Fukunishi S, Genda T, Abe H, Hotta N, Tsuji K, Ogawa C, Tachi Y, Shima T, Shimada N, Kondo C, Akahane T, Aizawa Y, Tanaka Y, Kumada T, Iwakiri K.

Aliment Pharmacol Ther. 2019 May;49(9):1230-1241. doi: 10.1111/apt.15218. Epub 2019 Mar 14.

PMID:
30873651
32.

Real-world virological efficacy and safety of daclatasvir/asunaprevir/beclabuvir in patients with chronic hepatitis C virus genotype 1 infection in Japan.

Takaguchi K, Toyoda H, Tsutsui A, Suzuki Y, Nakamuta M, Imamura M, Senoh T, Nagano T, Tada T, Tachi Y, Hiraoka A, Michitaka K, Shibata H, Joko K, Okubo H, Tsuji K, Takaki S, Watanabe T, Ogawa C, Chayama K, Kumada T, Kudo M, Kumada H.

J Gastroenterol. 2019 Aug;54(8):742-751. doi: 10.1007/s00535-019-01568-8. Epub 2019 Mar 8.

PMID:
30848363
33.

Role of Frontal Functions in Executing Routine Sequential Tasks.

Niki C, Kumada T, Maruyama T, Tamura M, Muragaki Y.

Front Psychol. 2019 Feb 6;10:169. doi: 10.3389/fpsyg.2019.00169. eCollection 2019. No abstract available.

34.

Utility of FIB4-T as a Prognostic Factor for Hepatocellular Carcinoma.

Kariyama K, Nouso K, Toyoda H, Tada T, Hiraoka A, Tsuji K, Itobayashi E, Ishikawa T, Wakuta A, Oonishi A, Kumada T, Kudo M, Group OBOTRPEFHRS, Group H.

Cancers (Basel). 2019 Feb 10;11(2). pii: E203. doi: 10.3390/cancers11020203.

35.

Task-irrelevant optic flow guides attention in visual search.

Higuchi Y, Inoue S, Endo T, Kumada T.

Atten Percept Psychophys. 2019 Jul;81(5):1327-1345. doi: 10.3758/s13414-018-01646-8.

PMID:
30684207
36.

Comparison of liver stiffness assessment by transient elastography and shear wave elastography using six ultrasound devices.

Iijima H, Tada T, Kumada T, Kobayashi N, Yoshida M, Aoki T, Nishimura T, Nakano C, Ishii A, Takashima T, Sakai Y, Aizawa N, Nishikawa H, Ikeda N, Iwata Y, Enomoto H, Ide YH, Hirota S, Fujimoto J, Nishiguchi S.

Hepatol Res. 2019 Jun;49(6):676-686. doi: 10.1111/hepr.13319. Epub 2019 Mar 5.

PMID:
30680865
37.

Liver Resection for Multiple Hepatocellular Carcinomas: A Japanese Nationwide Survey.

Fukami Y, Kaneoka Y, Maeda A, Kumada T, Tanaka J, Akita T, Kubo S, Izumi N, Kadoya M, Sakamoto M, Nakashima O, Matsuyama Y, Kokudo T, Hasegawa K, Yamashita T, Kashiwabara K, Takayama T, Kokudo N, Kudo M; Liver Cancer Study Group of Japan.

Ann Surg. 2019 Jan 16. doi: 10.1097/SLA.0000000000003192. [Epub ahead of print]

PMID:
30672806
38.

Influence of renal dysfunction on dose reduction and virologic efficacy of regimens combining ribavirin and all-oral direct acting antivirals in patients with chronic hepatitis C virus infection.

Nakashima M, Toyoda H, Tada T, Mizuno K, Iio E, Tanaka Y, Sugiyama T, Yoshimura T, Kumada T.

Hepatol Res. 2019 May;49(5):512-520. doi: 10.1111/hepr.13311. Epub 2019 Feb 7.

PMID:
30628746
39.

[Case of papillary cholangiocarcinoma with curative resection after long-term follow-up].

Takeda A, Kanamori A, Maeda A, Kumada T.

Nihon Shokakibyo Gakkai Zasshi. 2019;116(1):88-98. doi: 10.11405/nisshoshi.116.88. Japanese.

PMID:
30626859
40.

Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions: Multicenter analysis.

Hiraoka A, Kumada T, Kariyama K, Takaguchi K, Atsukawa M, Itobayashi E, Tsuji K, Tajiri K, Hirooka M, Shimada N, Shibata H, Ishikawa T, Ochi H, Tada T, Toyoda H, Nouso K, Tsutsui A, Itokawa N, Imai M, Joko K, Hiasa Y, Michitaka K; Real-life Practice Experts for HCC (RELPEC) Study Group, HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan).

Cancer Med. 2019 Jan;8(1):137-146. doi: 10.1002/cam4.1909. Epub 2018 Dec 21.

41.

Impact of albumin-bilirubin grade on survival in patients with hepatocellular carcinoma who received sorafenib: An analysis using time-dependent receiver operating characteristic.

Tada T, Kumada T, Toyoda H, Tsuji K, Hiraoka A, Michitaka K, Deguchi A, Ishikawa T, Imai M, Ochi H, Joko K, Shimada N, Tajiri K, Hirooka M, Koizumi Y, Hiasa Y, Tanaka J.

J Gastroenterol Hepatol. 2019 Jun;34(6):1066-1073. doi: 10.1111/jgh.14564. Epub 2019 Feb 27.

PMID:
30549320
42.

Efficacy and safety of ombitasvir/paritaprevir/ritonavir and ribavirin for chronic hepatitis patients infected with genotype 2a in Japan.

Atsukawa M, Tsubota A, Toyoda H, Takaguchi K, Nakamuta M, Watanabe T, Tada T, Tsutsui A, Ikeda H, Abe H, Kato K, Uojima H, Ikegami T, Asano T, Kondo C, Koeda M, Okubo T, Arai T, Iwashita-Nakagawa A, Itokawa N, Kumada T, Iwakiri K.

Hepatol Res. 2019 Apr;49(4):369-376. doi: 10.1111/hepr.13292. Epub 2019 Jan 2.

PMID:
30485638
43.

Utility of Attenuation Coefficient Measurement Using an Ultrasound-Guided Attenuation Parameter for Evaluation of Hepatic Steatosis: Comparison With MRI-Determined Proton Density Fat Fraction.

Tada T, Kumada T, Toyoda H, Kobayashi N, Sone Y, Oguri T, Kamiyama N.

AJR Am J Roentgenol. 2019 Feb;212(2):332-341. doi: 10.2214/AJR.18.20123. Epub 2018 Nov 26.

PMID:
30476453
44.

Circulating let-7 Levels in Serum Correlate With the Severity of Hepatic Fibrosis in Chronic Hepatitis C.

Matsuura K, Aizawa N, Enomoto H, Nishiguchi S, Toyoda H, Kumada T, Iio E, Ito K, Ogawa S, Isogawa M, Alter HJ, Tanaka Y.

Open Forum Infect Dis. 2018 Oct 22;5(11):ofy268. doi: 10.1093/ofid/ofy268. eCollection 2018 Nov.

45.

Automatic detection of mind wandering in a simulated driving task with behavioral measures.

Zhang Y, Kumada T.

PLoS One. 2018 Nov 12;13(11):e0207092. doi: 10.1371/journal.pone.0207092. eCollection 2018.

46.

Possible involvement of Enterococcus infection in the pathogenesis of chronic pancreatitis and cancer.

Maekawa T, Fukaya R, Takamatsu S, Itoyama S, Fukuoka T, Yamada M, Hata T, Nagaoka S, Kawamoto K, Eguchi H, Murata K, Kumada T, Ito T, Tanemura M, Fujimoto K, Tomita Y, Tobe T, Kamada Y, Miyoshi E.

Biochem Biophys Res Commun. 2018 Dec 2;506(4):962-969. doi: 10.1016/j.bbrc.2018.10.169. Epub 2018 Nov 3.

PMID:
30401562
47.

The impact of HCV eradication by direct-acting antivirals on the transition of precancerous hepatic nodules to HCC: A prospective observational study.

Toyoda H, Kumada T, Tada T, Mizuno K, Sone Y, Akita T, Tanaka J, Johnson PJ.

Liver Int. 2019 Mar;39(3):448-454. doi: 10.1111/liv.13987. Epub 2018 Nov 2.

PMID:
30312003
48.

Efficacy of direct-acting antiviral treatment in patients with compensated liver cirrhosis: A multicenter study.

Itokawa N, Atsukawa M, Tsubota A, Ikegami T, Shimada N, Kato K, Abe H, Okubo T, Arai T, Iwashita AN, Kondo C, Mikami S, Asano T, Matsuzaki Y, Toyoda H, Kumada T, Iio E, Tanaka Y, Iwakiri K.

Hepatol Res. 2019 Feb;49(2):125-135. doi: 10.1111/hepr.13256. Epub 2018 Nov 13.

PMID:
30307682
49.

Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection.

Chan AWH, Zhong J, Berhane S, Toyoda H, Cucchetti A, Shi K, Tada T, Chong CCN, Xiang BD, Li LQ, Lai PBS, Mazzaferro V, García-Fiñana M, Kudo M, Kumada T, Roayaie S, Johnson PJ.

J Hepatol. 2018 Dec;69(6):1284-1293. doi: 10.1016/j.jhep.2018.08.027. Epub 2018 Sep 18.

50.

Efficacy and safety of elbasvir/grazoprevir for Japanese patients with genotype 1b chronic hepatitis C complicated by chronic kidney disease, including those undergoing hemodialysis: A post hoc analysis of a multicenter study.

Atsukawa M, Tsubota A, Toyoda H, Takaguchi K, Kondo C, Okubo T, Hiraoka A, Michitaka K, Fujioka S, Uojima H, Watanabe T, Ikeda H, Asano T, Ishikawa T, Matsumoto Y, Abe H, Kato K, Tsuji K, Ogawa C, Shimada N, Iio E, Mikami S, Tanaka Y, Kumada T, Iwakiri K.

J Gastroenterol Hepatol. 2019 Feb;34(2):364-369. doi: 10.1111/jgh.14447. Epub 2018 Sep 14.

PMID:
30144366

Supplemental Content

Loading ...
Support Center